The Effects of Brain Tumours upon Medical Decision-Making Capacity.


Journal

Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967

Informations de publication

Date de publication:
02 05 2019
Historique:
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 19 8 2020
Statut: epublish

Résumé

Informed consent is the integral part of good medical practice in patients with brain tumours. Capacity to consent may be affected by the brain disorder or its treatment. We intend to draw upon the current neuro-oncology literature to discuss the influence intracranial tumours have upon patients' capacity to consent to treatment and research. We performed a systematic review of studies of capacity to consent for treatment or research in patients with intracranial tumours. The search retrieved 1597 papers of which 8 were considered eligible for review. Although there are obvious inherent limitations to solely assessing cognition, most research consistently demonstrated increased risk of incapacity in brain tumour patients with cognitive impairment. Specific items in cognitive screening batteries, for example Semantic Verbal Fluency Test (SVFT), Hopkins Verbal Learning Test (HVLT-Recall), and Trail Making Test A/B (TMT), are simple, easily applied tests that may act as significant red flags to identify patients at increased risk of incapacity and who subsequently will require additional cognitive/psychiatric evaluation or more formal tests for capacity to consent for treatment or research.

Identifiants

pubmed: 31049786
doi: 10.1007/s11912-019-0793-3
pii: 10.1007/s11912-019-0793-3
pmc: PMC6495430
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

55

Références

Int J Law Psychiatry. 2001 Mar-Jun;24(2-3):267-83
pubmed: 11436630
Psychiatr Serv. 2002 Oct;53(10):1322-4
pubmed: 12364686
J Neurooncol. 2003 Jul;63(3):223-4
pubmed: 12892227
Lancet. 2004 Oct 16-22;364(9443):1421-7
pubmed: 15488217
Neuropsychol Rev. 2004 Sep;14(3):131-42
pubmed: 15673234
Clin Psychol Rev. 2005 Nov;25(7):954-74
pubmed: 15964671
Br J Psychiatry. 2005 Oct;187:379-85
pubmed: 16199799
Clin Med (Lond). 2005 Nov-Dec;5(6):580-4
pubmed: 16411355
J Gen Intern Med. 2006 Jan;21(1):78-83
pubmed: 16423129
Am J Psychiatry. 2006 Aug;163(8):1323-34
pubmed: 16877642
Brain. 2007 Apr;130(Pt 4):898-914
pubmed: 17121742
Neurology. 2007 Oct 9;69(15):1528-35
pubmed: 17923615
J Int Neuropsychol Soc. 2007 Nov;13(6):1047-59
pubmed: 17942022
BMJ. 2008 Jun 30;337:a448
pubmed: 18595931
Acta Neurochir (Wien). 2009 Apr;151(4):357-62
pubmed: 19224120
J Neurooncol. 2010 Jan;96(2):241-7
pubmed: 19575147
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Geriatr Psychiatry Neurol. 2010 Mar;23(1):3-8
pubmed: 19661490
J Neurooncol. 2010 Jan;96(1):103-14
pubmed: 19957014
Neurology. 2009 Dec 15;73(24):2086-92
pubmed: 20018637
Res Gerontol Nurs. 2009 Apr;2(2):103-11
pubmed: 20077971
Stroke. 2010 Jun;41(6):1290-3
pubmed: 20378863
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1244-52
pubmed: 20598457
J Clin Oncol. 2010 Aug 20;28(24):3844-50
pubmed: 20644102
Rehabil Psychol. 2008 Nov 1;53(4):486-497
pubmed: 20686627
Neurosci Biobehav Rev. 2011 Jan;35(3):729-41
pubmed: 20869395
J Neurooncol. 2011 Sep;104(3):623-7
pubmed: 21318320
Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42
pubmed: 21666852
Brain Res. 2012 Jan 5;1428:3-12
pubmed: 21676379
Br J Neurosurg. 2012 Feb;26(1):28-31
pubmed: 21815735
Br J Psychiatry. 2011 Nov;199(5):355-6
pubmed: 22045941
Ther Adv Neurol Disord. 2011 Nov;4(6):385-407
pubmed: 22164192
J Neurooncol. 2012 Oct;110(1):59-67
pubmed: 22798208
J Empir Res Hum Res Ethics. 2012 Dec;7(5):63-70
pubmed: 23324205
J Clin Nurs. 2013 Sep;22(17-18):2387-403
pubmed: 23650907
World J Urol. 2014 Apr;32(2):385-91
pubmed: 23756991
BMC Med Ethics. 2013 Dec 13;14:54
pubmed: 24330745
Neurology. 2014 Aug 5;83(6):537-41
pubmed: 24991034
Brain. 2014 Sep;137(Pt 9):2532-45
pubmed: 25027503
Nat Rev Neurol. 2014 Sep;10(9):487-8
pubmed: 25112511
Neuro Oncol. 2015 Apr;17(4):580-7
pubmed: 25227126
Psychooncology. 2015 Nov;24(11):1448-55
pubmed: 25613039
Cancer. 2015 Jun 15;121(12):2013-9
pubmed: 25735262
Front Oncol. 2015 Mar 11;5:60
pubmed: 25815273
Neurooncol Pract. 2015 Mar;2(1):13-19
pubmed: 26034637
Neuropsychiatr Dis Treat. 2015 Jun 10;11:1413-20
pubmed: 26089669
J Int Neuropsychol Soc. 2015 Jul;21(6):412-8
pubmed: 26149751
Neuro Oncol. 2016 Mar;18(3):435-44
pubmed: 26385615
World Neurosurg. 2016 Jul;91:340-6
pubmed: 27072331
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Arch Clin Neuropsychol. 2016 Sep;31(6):530-40
pubmed: 27551024
Neuro Oncol. 2016 Dec;18(12):1595-1596
pubmed: 27880642
Ann Indian Acad Neurol. 2016 Oct;19(Suppl 1):S34-S39
pubmed: 27891023
J Neurosurg. 2017 Jun;126(6):2045-2050
pubmed: 28430037
J Appl Clin Med Phys. 2018 Jan;19(1):86-93
pubmed: 29125239
Sci Rep. 2017 Dec 19;7(1):17764
pubmed: 29259230
Am J Geriatr Psychiatry. 2018 May;26(5):523-531
pubmed: 29398351
BMC Cancer. 2018 Feb 21;18(1):218
pubmed: 29466961
N Engl J Med. 1988 Dec 22;319(25):1635-8
pubmed: 3200278
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820

Auteurs

Will Hewins (W)

Department of Clinical Neurosciences, Western General Hospital, Edinburgh, EH4 2XU, Scotland.
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK.

Karolis Zienius (K)

Department of Clinical Neurosciences, Western General Hospital, Edinburgh, EH4 2XU, Scotland.

James L Rogers (JL)

Tulane University, New Orleans, LA, USA.

Simon Kerrigan (S)

Department of Neurology, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.

Mark Bernstein (M)

Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, Canada.

Robin Grant (R)

Department of Clinical Neurosciences, Western General Hospital, Edinburgh, EH4 2XU, Scotland. robin.grant@nhslothian.scot.nhs.uk.
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK. robin.grant@nhslothian.scot.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH